University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > CME > HCV Infection > CME Posttest
CME Posttest on Management and Treatment of HCV Infection: Entering a New Era in 2011
grey line

You need to answer all questions correctly to earn continuing medical education credit.

1. Which of the following is NOT true regarding the addition of the new HCV protease inhibitors to the current standard of care (pegylated interferon and ribavirin) for the treatment of HCV?

radio buttons

2. Which of the following is associated with the use of a telaprevir-containing regimen in a genotype 1 HCV-infected, treatment-naive patient?

radio buttons

3. Which adverse event is more frequent in patients taking an HCV regimen with boceprevir compared with those taking an HCV regimen without an HCV protease inhibitor?

radio buttons

4. Owing to potential drug-drug interactions, increased doses of telaprevir are being studied in the setting of HIV/HCV coinfection when used concomitantly with which antiretroviral drug?

radio buttons

About | Site Map | Feedback | Subscribe | Donate | Disclaimer

UCSF - Center for HIV Information HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2013, Regents of the University of California.